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SELECTION OF THE MONTH 
Big Title: alfapump: a new treatment for refractory ascites 
 
Finite nucleos(t)ide analogue treatment for chronic hepatitis B 
The ongoing HCC risk after HBsAg loss 
Neurotropism of HEV revisited 
 
ENDOPLASMIC RETICULUM (ER) HOMEOSTASIS IN LIVER DISEASES 
Hepatic ER stress in obesity and hepatocellular carcinoma (HCC) 
Professional secretory cells such as hepatocytes communicate with their environment 
using secreted proteins and proteins displayed on the cell surface. In order to reach 
their destinations, these proteins must enter the secretory pathway via insertion into 
the ER, where they are folded and matured. It is important to know that the 
concentration of proteins within the ER lumen is approximately 100 mg/mL. Moreover, 
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the protein synthesis rate in hepatocytes is estimated to 13 million secretory proteins 
per minute. To accomplish such a thermodynamically unfavorable process in an 
overwhelmingly crowded environment, the cell expends a large amount of energy to 
ensure that this quantitative achievement does not come at the price of quality. 
Homeostasis within the ER lumen (in particular that of Ca2+ concentration which is 
much higher in the ER lumen than the cytosol), is meticulously monitored and 
maintained. A broad variety of insults can induce ER stress and lead to the 
activation of a coordinated adaptive program called the unfolded protein 
response (UPR), referred to as ERUPR. In response to the accumulation of unfolded 
proteins in the ER, the rate of general translation initiation is attenuated, the expression 
of ER resident protein chaperones and protein foldases is induced, the ER 
compartment proliferates, and ER-associated degradation is activated to eliminate the 
irreparably misfolded proteins. When the prosurvival efforts are exhausted, ER-stress 
related apoptosis commences. The outcome of the ERUPR may be beneficial or 
detrimental depending on the context. This issue of the Journal provides two examples 
of different outcomes induced by the deregulation of ER homeostasis. The first study 
by Wires et al. reports results of elegant experiments investigating the effect of high fat 
diet on ER Ca2+ homeostasis in rat livers. They found that dietary fat intake correlates 
with a decrease in ER calcium levels in the liver. These findings should be interpreted 
knowing that: first, a decrease in ER Ca2+ concentration can induce ERUPR, and second 
it has long been known that obesity can be associated with ER stress and subsequent 
induction of chronic ERUPR in the liver, resulting in hepatic insulin resistance. Therefore, 
the findings by Wilkes et al. strongly suggest that decreased Ca2+ concentration 
in hepatocyte ER lumen may be a primary inducer of inappropriate ERUPR in the 
liver of obese individuals. The second study is an example of beneficial ERUPR. In this 
study, Ma et al. first showed that acyl-CoA desaturase (also known as stearoyl-CoA 
desaturase; encoded by SCD) was overexpressed in HCC and correlated with poor 
survival. Next, using different approaches (including pharmacological inhibitors) they 
found that acyl-CoA desaturase inhibition induced ERUPR which suppressed liver 
tumor-initiating cells and sorafenib resistance. They concluded that “targeting SCD1 
alone or in combination with sorafenib might be a novel personalized medicine 
against HCC.” 
 
GENETIC LIVER DISEASES 
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A genetic variation associated with macro-AST 
Macro-aspartate aminotransferase (macro-AST) is a rare genetic condition 
characterized by persistent elevation of AST levels, due to association of the protein 
with immunoglobulins. AST is encoded by GOT1 (for glutamic-oxaloacetic 
transaminase 1). In this issue of the Journal, Kulecka et al. genotyped 32 patients with 
suspected familial macro-AST. An allele in GOT1 (rs374966349 [C] encoding 
p.Gln208Glu) was detected in 54% of probands from suspect families, while its 
prevalence in healthy controls was only 0.18%. In silico analysis demonstrated that a 
negatively charged glutamate on the surface of the protein encoded by GOT1 could 
strongly anchor serum immunoglobulins. This interesting study strongly suggest that 
testing for this genetic variant may be useful in diagnosis of macro-AST.  
 
ALCOHOLIC LIVER DISEASE 
MIF as a potential molecular driver of alcoholic liver injury 
The only effective therapy for patient with alcoholic liver disease is alcohol abstinence. 
Identifying molecular drivers could help the development of new targeted therapies. In 
this issue of the Journal, Marin et al. performed a translational study to assess the role 
of macrophage migration inhibitory factor (MIF), a powerful inflammatory cytokine. 
They first found that cultured hepatocytes release MIF in response to ethanol. Then, 
using different transgenic models in mice, they provide evidence that ethanol intake 
upregulates MIF in hepatocytes that mediates the inflammatory changes in the liver. In 
patients with alcoholic hepatitis, MIF was found overexpressed in hepatocytes. 
Interestingly, serum levels of MIF in the suprahepatic vein were increase and 
correlated with disease severity. These data provide evidence that hepatocyte- 
derived MIF is a molecular driver of ALD and represents a potential novel target 
for therapy.  
 
HEPATITIS C VIRUS (HCV) INFECTION 
DAA and HCC risk - not so hot! 
Whether interferon-free direct-acting antiviral (DAA) therapy has similar effects on 
early HCC occurrence or recurrence as interferon-based therapy is still a matter of 
debate. In a retrospective review of a large prospective database (n=1897), Nagata et 
al. were not able to demonstrate any significant difference in both HCC occurrence as 
well as recurrence rates between the groups treated with IFN-based or IFN-free 
4 
 
therapies. Indeed, viral eradication had an early inhibitory effect on 
hepatocarcinogenesis irrespective of the type of antiviral therapy. Biomarkers for 
HCC development were identified, and among others, authors described for the first 
time Wisteria floribunda agglutinin positive Mac-2 binding protein (WFA+M2BP) as a 
new predictor associated with HCC development after SVR, independently from the 
stage of liver fibrosis. This study adds to the increasing body evidence highlighting the 
importance of long-term HCC surveillance of certain risk groups after viral eradication 
but speaks against a specific role of the type of antiviral treatment concerning the tumor 
risk in general. 
 
HEPATITIS B AND C DIAGNOSIS 
Don’t be late 
Late diagnosis of HBV and HCV represents a missed opportunity to reduce the risk of 
serious liver disease. The timing of HBV and HCV diagnoses relative to the detection 
of decompensated cirrhosis and hepatocellular carcinoma was measured between 
1990 and 2012 by Samji et al. in the British Columbia Hepatitis Testers Cohort 
(n=90,510). Although marked improvement in late diagnosis has been observed 
for both HBV and HCV over time, still between 46%-49% of HBV and between 
31%-40% of HCV cases were diagnosed late. The authors make an important point 
that timely diagnosis can reduce morbidity and mortality, particularly in the era of highly 
effective therapy, and that screening for viral hepatitis remains important as not all 
affected persons report risk factors. 
 
HEPATITIS B VIRUS (HBV) INFECTION 
Less can be more – Finite NA treatment in HBeAg-negative chronic hepatitis B, 
the ongoing risk of HCC after HBsAg loss – is it all about gender and age? 
Stopping nucleos(t)ide analogue (NA) treatment in chronically HBV-infected patients 
often leads to viral relapse and therefore life-long therapy is usually considered the 
optimal strategy. However, uncontrolled studies suggest that a relapse-associated 
HBV-specific immune response may lead to long-term remission even with HBsAg 
loss. The controlled study by Berg et al. is the first that investigated the potential to 
discontinue tenofovir disoproxil fumarate (TDF) therapy in HBeAg-negative patients in 
a randomized fashion. Main findings of this proof-of-concept study were that 2 
years after treatment cessation, 50% of the patients remained free of therapy and 
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a total of 19% lost HBsAg, whereas no significant decline in HBsAg levels were 
observed in those who continued on TDF. Although the sample size of this proof-
of-concept study was small, the findings open the way for a more individualized 
strategy in the long-term management of NA-treated patients. Further studies should 
concentrate on the issue which group of patients are most likely to benefit from this 
finite approach. 
Genetic instability due to integration of parts of the HBV DNA into the human genome 
as well as the life-long persistence of covalently closed circular DNA serve as 
explanations for the ongoing risk of HCC development in HBV-infected patients even 
after loss of HBsAg. Previous studies suggested that the risk is especially high for male 
patients with advanced fibrosis, and being above 50 years old at the time of HBsAg 
seroclearance. The study by Yip et al. aimed to evaluate the risk of HCC after HBsAg 
seroclearance, and the impact of gender on HCC development in a large group of 
4,568 patients from Hong Kong. The cumulative HCC incidence after HBsAg 
seroclearance was 0.9%, 1.3% and 1.5% at one, three and five years of follow-up, 
respectively. Age above 50 years and male gender were two independent HCC 
risk factors, whereas female patients aged ≤50 years had no risk of HCC 
development within 5 years. This study has important clinical implications as HCC 
surveillance may not be necessary for female patients with HBsAg seroclearance at 
50 years or younger, but may still be cost-effective for other patients. 
 
HEPATITIS E VIRUS (HEV) INFECTION 
Neurotropism of HEV revisited 
Neurologic illnesses are by far the most commonly reported extrahepatic manifestation 
of HEV infection but the causality has not yet been established. Dalton et al. addressed 
this question by performing a prospective study in which consecutive patients with 
acute non-traumatic neurological illnesses attending four hospitals in three European 
countries were systematically screened for HEV infection. They observed an at least 
ten times higher point prevalence of HEV viremia in neurological patients as compared 
to recent studies in blood donors. The most striking observation of the current 
study is that three of five cases of neuralgic amyotrophy diagnosed during the 
study were HEV-associated. This study underlines the neurotropism of HEV, and 
provides evidence of a specific, likely causal, association between neuralgic 
amyotrophy and HEV infection. The intriguing finding that ALT levels were normal or 
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only modestly elevated in the HEV-infected neurological patients could imply that some 
strains of HEV are primarily neurotropic rather than hepatotropic. 
 
HCC 
Predictors of sorafenib benefit, use of AGREE II instrument for quality control of 
guidelines 
Two phase III, randomized, double-blind, placebo-controlled trials of sorafenib, have 
shown that this treatment significantly prolonged overall survival in patients with 
unresectable HCC. Bruix et al. here report their assessment of prognostic factors for 
HCC and predictive factors of sorafenib benefit, using a pooled exploratory analysis 
from these placebo-controlled phase III studies. They show that presence of 
macroscopic vascular invasion, high alpha-fetoprotein, and high neutrophil-to-
lymphocyte ratio (NLR) were predictors of poor overall survival. Sorafenib benefit was 
consistently observed irrespective of prognostic factors. Lack of extrahepatic spread, 
presence of HCV, and lower NLR were predictive of longer overall survival with 
sorafenib. 
The Appraisal of Guidelines for Research & Evaluation (AGREE II) is the only validated 
instrument to assess the methodological quality of guidelines. Azoulay et al. evaluated 
the methodological quality of existing guidelines for the resection of HCC using the 
AGREE II instrument. They reveal that the methodological quality of guidelines for the 
surgical management of HCC is generally poor. Future guideline development 
should be informed by the use of the AGREE II instrument. Guidelines based 
upon high quality evidence could improve stratification of patients and 
individualized treatment strategies. 
 
CIRRHOSIS 
alfapump insertion effectively reduces the need for large volume paracentesis 
in patients with refractory ascites, gut-derived endotoxin contributes to 
endothelial dysfunction and Factor VIII release 
Treatment options for patients with refractory ascites are limited to liver transplantation 
and a selected group of patients benefit from insertion of transjugular intrahepatic 
portosystemic stent-shunt. The rest of the patients require repeated large volume 
paracentesis (LVP). alfapump is a novel, fully implantable, automated, low flow system 
that automatically moves ascitic fluid into the urinary bladder. Bureau et al. describe 
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the results of the first, multicenter, European study comparing alfapump with 
LVP. The trial data confirm that insertion of the alfapump is associated with 
significant reduction in the need for LVP, improvements in the quality of life and 
nutritional state. The incidence of acute kidney injury was higher in the alfapump 
treated patients but this did not impact negatively on survival. Further improvements in 
the technology and regular albumin infusions may allow the alfapump to emerge as an 
important new therapeutic for this group of patients. 
The mechanisms underlying the increased risk of portal vein thrombosis (PVT) in 
patients with cirrhosis is unclear. Studies have suggested that an elevated 
concentration of factor VIII was associated with risk of PVT. Carnevale et al. describe 
the results of an important study demonstrating an association between 
endotoxemia, Factor VIII and von Willebrand’s factor levels cirrhosis patients. 
They go on to show in isolated endothelial cells that blocking toll-like receptor 4, which 
inhibits endotoxin signaling prevents LPS-induced release of Factor VIII from the 
endothelial cells. The result of this study implicates the microbiome in the pathogenesis 
of PVT and may have implications for future preventative approaches for PVT.  
 
ACUTE LIVER FAILURE 
MiR 1224 negatively affects the outcome of acute liver failure (ALF) by inhibiting 
cell proliferation 
The outcome of patients with ALF is determined by a balance between cell death and 
regeneration. Strategies to enhance regeneration of patients with ALF are lacking. Roy 
et al. investigated the role of micro RNA 1224, which is a small non-coding RNA 
that is expressed in hepatocytes. Their important data suggests that during 
acute injury in a mouse model, miR1224 was expressed in the hepatocytes and 
this was associated with reduced proliferation and increased apoptosis. These 
data were confirmed in the liver of patients with ALF. Furthermore, miR 1224 could be 
detected in the serum and elevated levels predicted poorer survival. These novel data 
provide a potential novel biomarker and also a therapeutic target. 
 
LIVER TRANSPLANTATION 
Transplantation of organs from deceased donors (DCD) to patients with primary 
sclerosing cholangitis (PSC) does not impact outcomes 
Liver transplantation is the only treatment known to prolong the survival of patients with 
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PSC. In order to increase the donor pool, greater numbers of organs from donors after 
death are being used for transplantation. One of the complications of using these 
organs is the risk of post-transplant biliary strictures. Liver transplantation for PSC 
across many centers is restricted to the usage of grafts from brain dead donors (DBD) 
due to apprehensions of post-transplant biliary complications. Trivedi et al. analyzed 
outcomes of liver transplantation of PSC patients who received either organs 
from brain dead donors (n=108) and deceased donors (n=35). Intriguingly, their 
data show that there was no significant difference in the outcome of patients 
receiving DBD or DCD graft in terms of graft and patient survival. The risk of 
post-transplant biliary strictures was also similar between the groups. Increasing 
the donor pool by allowing patients with PSC to be transplanted with DCD organs has 
the potential reducing deaths on the waiting list. 
